



College of
Pharmacy

2026-2028 Fellowship Program

Table of Contents



About Bayer.....3-6

Leadership Team.....7

Pharmaceuticals Division.....8-9

Medical Affairs Communications.....8

U.S. Regulatory Affairs.....9

About HUCOP Pharmaceutical Fellowship Program.....10

Howard University Information & Application Process.....11-12





On August 1, 1863, dye salesman Friedrich Bayer and master dyer Johann Friedrich Wescott founded the general partnership Friedr. Bayer et comp.,” and the company grew to become a joint stock company in 1881.

1863-1881: The Early Years



Gerhard Domagk discovered the therapeutic effect of sulfonamides, with one active ingredient from this class of substances being

launched in 1935 as Prontosil – a key breakthrough in the chemotherapy of infectious diseases for which Domagk received the Nobel Prize in 1939.

1925-1945: A Time of Inventions



Bayer acquired the North American self-medication business of Sterling Winthrop in 1994. In 1995, the U.S.-based Miles Inc. was renamed Bayer Corporation.

1988-2001: Transformation and Globalization



In 2010, Bayer celebrated fifty years of successful family planning with the pill: first given regulatory approval in 1960. Till this day Bayer is a global market leader in the field of hormonal contraception.


2010-2014: Pioneers in Women's Health

1881-1914: Becoming an International Company



Bayer develops into a chemical company with international operations. Research efforts gave rise to numerous intermediates, dyes and pharmaceuticals, including the "Drug of the Century," Aspirin®, which was developed by Felix Hoffmann and launched onto the market in 1899.

1974-1988: Expansion of Pharmaceutical Research




Successful products to emerge from Bayer's research laboratories in this period included the cardiovascular drug Adalat®, Bayer's first broad-spectrum antibiotic from the class of quinolones Ciprobay® and the antifungal crop protection product Bayleton®.

2001-2010: Reorganization and Growth



Bayer completes the acquisition of the Roche consumer health business in January 2005, advancing to become one of the world's top suppliers of nonprescription medicines. In December 2005, the U.S. FDA approves Nexavar™ for the treatment of advanced renal cell carcinoma. In December of 2009, a Bayer team wins the German Future Prize for the development of the new anticoagulant (Xarelto™)*.

2014-present: Investing in the Future



Bayer strengthens its oncology business with the acquisition of Algeta in March 2014. In October of the same year, Bayer acquires the consumer care unit of U.S.-based Merck & Co. More recently in 2019, through the full acquisition of BlueRock Therapeutics, Bayer is committed to building a leading position in cell therapy.



Pharmaceuticals




Consumer Health





Bayer's vision "Health for All, Hunger for None" comes to life through our Dynamic Shared Ownership (DSO) model, which empowers individuals and teams to bring their authentic selves to work in pursuit of greater impact for patients, caregivers, and key stakeholders. By embracing our leadership principles (VACC), operational mechanics (VITAL), and DSO behaviors, we break down barriers, unlock collective potential, and elevate performance to new heights.





For and with patients, consumers, and other stakeholders:

WHAT WE FOCUS ON

Mission focus

Focus on outcomes

We define and deliver highest impact outcomes.

HOW WE SHOW UP

Enabling mindsets and behaviors

Be our best selves and include others

We respect differences, embrace inclusion, and show up as our best selves.

HOW WE ORGANIZE

More power in the hands of the people doing the work

Collaborate with accountability

We collaborate and hold each other accountable in and across teams.

HOW WE CREATE VALUE

Customers and products at the center

Co-create for customers

We are close to the customer and co-create solutions for their needs.

HOW WE GET WORK DONE

Faster work cycles and continual evolution

Act, learn fast and evolve

We work in 90-day cycles, learn quickly, and continually develop.

Leadership Team

Program Directors



Executive Sponsors



Alison Maloney, PhD, MBA, MFS
Head of Regulatory Affairs, North America
Executive Sponsor



Mark Rametta, DO, FACOI, FACP
Senior Medical Director, US Medical Affairs, Specialty Medicine, Pipeline Products
Executive Sponsor

Pharmaceutical Program Directors



Larry McCullum, PharmD, MPhil, RPh
Director, Medical Affairs Strategy, Oncology
Medical Affairs Communications
Fellowship Director



Michael Cunha
Senior Director, Regulatory Policy and Science
Fellowship Director

BAYER MEDICAL AFFAIRS COMMUNICATIONS

2-Year Fellowship (July 2026-2028)
Recruiting One Fellow

We seek talented innovative, solution-minded individuals to develop into value adding team members. The Medical Affairs Communications Fellow will work within a high performing, engaging, inclusive and scientifically adept environment with supportive leadership who prioritize delivering innovative effective solutions to our patients and customers.

Program Description

The Bayer Medical Affairs Communications partnership with the Howard University College of Pharmacy Fellowship Program affords selected candidate(s) the following:

Gain Expertise in Multiple Therapeutic Areas:

- Build a strong foundational background in the Oncology, Cardiovascular Renal and Hematology therapeutic areas. Gain expertise in Core Medical Affairs Communication functional responsibilities (e.g., promotional review, content development, medical strategy support, dossier development support, product launch preparation, congress support, etc.)
- Work collaboratively and across Medical Affairs to acquire project management, digital innovation, Artificial Intelligence (AI), Governance, publications, RWE, HEOR, and Medical Scientific Liaison experience

Provide an Opportunity for Fellow to:

- Work with Preceptors, Program Directors, Medical Directors, Publications and Digital Innovation teams to acquire project management skills by working on various projects.
- To conduct longitudinal research in Medical Affairs Communications to the department and to an industry-wide conference.
- Work with Medical Affairs Communications Program Director to develop a tailored second-year program structure based on the Fellows specific areas of interest aligned with the DSO model and participate in Market Place initiatives.



Mark Rametta, DO, FACOI, FACP
Senior Medical Director, US Medical
Affairs, Specialty Medicine, Pipeline
Products
Executive Sponsor



Larry McCullum, PharmD, MPhil, RPh
Director, Medical Affairs Strategy,
Oncology
Medical Affairs Communications
Fellowship Director



Sydni Newsome, PharmD, RPh
Florida A&M University College of Pharmacy,
2nd year Fellow



Jaylen Barnes, PharmD
Campbell University College of Pharmacy &
Health Sciences,
1st year Fellow

Location: Whippany, NJ



BAYER REGULATORY AFFAIRS

2-Year Fellowship (July 2026-2028)
Recruiting One Fellow

The Bayer US Regulatory Affairs fellowship is a comprehensive program designed to develop highly competent regulatory affairs professionals and seeks to attract qualified PharmD candidates who wish to gain extensive training.

Program Description

This fellowship aims to develop well-rounded regulatory affairs professionals by providing fellows with the foundational skills and resources they need to succeed, by offering exposure to different regulatory functions, therapeutic areas, and stages of drug development. Through the rotational structure, fellows will gain hands on experience in regulatory affairs, working on projects with various teams to address real-world outcomes.

Gain Expertise in Multiple Therapeutic Areas:

- Therapeutic Areas of Opportunity: Cardiology, Nephrology & Thrombosis; Hematology; Oncology; Women's Health Care
- Gain comprehensive exposure to USA regulatory affairs through rotations in policy, strategy, advertising and promotion, labeling, and CMC.

Provide an Opportunity for Fellow to:

- Support interactions with FDA through the preparation of regulatory dossiers including Investigational New Drug (IND) applications, New Drug Applications (NDAs), and Biologics License Applications (BLAs)
- Partner with regulatory team members to learn to develop regulatory strategy and guide global project teams
- Coordinate team activities to obtain written and oral FDA feedback on drug development and life cycle management topics
- Maintain marketed products to ensure compliance with regulatory requirements and optimal labeling
- Support U.S. Advertising and Promotion activities including promotional material reviews and FDA submissions
- Work with US CMC to develop strategy, submissions and maximize FDA interactions
- Collaborate cross-functionally with key stakeholders within the organization to develop and clearly communicate Bayer's positions on US regulatory policies



Alison Maloney, PhD, MBA, MFS
Head of Regulatory Affairs, North America
Executive Sponsor



Michael Cunha
Senior Director, Regulatory Policy and
Science
Fellowship Director



Sohyeon Park, PharmD, RPh
Jefferson College of Pharmacy,
2nd year Fellow

Howard University Pharmaceutical Industry Fellowships (HUPIF)



Envisioned in 2012

Howard University College of Pharmacy Pharmaceutical Industry Fellowship Program (HUPIF) serves to develop post-doctoral fellows with competency and the skill set necessary to serve as integral leaders in academia, biopharmaceutical industry, policy arena, research enterprise, and the U.S Government inclusive of the Food and Drug Administration (FDA). Our fellows will participate in cutting-edge projects and provide expertise on unique patient health challenges in partnership with their respective fellowship programs.

13 Partner Companies

The HUPIF Program has partnerships with over 13 biopharmaceutical companies. The fellowship program strives to be a premier program by offering opportunities in teaching, learning, research, leadership, and service locally and globally.

MISSION:

We strive to provide premiere professional development fellowships to post-doctoral candidates with high academic, scholarship, and leadership potential.

VISION

We aim to be a model for academic-industrial partnerships in the development of highly talented, innovative post-doctoral professionals that provide impactful and transformative support to the organizations and the communities that they serve.

VALUES

We value integrity, professionalism, collaboration, cultural competence, and a commitment to excellence.

ABOUT HOWARD UNIVERSITY

FELLOWSHIP PROGRAM



The Howard University College of Pharmacy (HUCOP) stands as the singular college of pharmacy in our nation's capital, a legacy that dates to 1868. Since our establishment, HUCOP has been a stalwart provider of pharmacy education, consistently nurturing leaders who go on to make their mark on the global stage.

At HUCOP, our focus remains delivering a contemporary pharmacy education while paving new paths through scholarship, research, and professional growth.

Our distinction as the top ranked Program, as recognized by U.S. News & World Report is proof of our unwavering commitment to excellence across various domains.

Envisioned in 2012, the pioneering HUCOP Pharmaceutical Industry Fellowship Program places a special emphasis on "taking the limits off" our fellows while taking them from "success to significance". We seek candidates that represent America and the Global community. They must have a proven track record of excellence, exceptional communication skills both written and oral, a receptive aptitude for mentorship, and an innate reservoir of leadership potential primed for future C-suite consideration.

Structured as immersive experiences spanning one to two years, our post-doctoral fellowships empower participants with hands on training in academic, biopharmaceutical, clinical, medical, corporate, research and regulatory spheres.

We extend sincere gratitude to our valued partners, dedicated preceptors, and diligent staff members. Their commitment to guiding our fellows through role modeling, coaching, and professional advancement remains instrumental to our shared success.

Excellence in Truth and Service,

Dr. Earl B. Ettienne
Assistant Dean of Graduate Programs and Industry Partnerships
HUCOP Fellowship Program Team



Application & Recruitment Process

Eligibility Criteria

To be eligible for a Pharmaceutical Industry Fellowship at HUCOP, candidates should have graduated from an accredited College/ University with a Pharm.D. or PhD, in Pharmaceutical Sciences or related life sciences discipline, or will be by the start of the Fellowship. Candidates must hold a degree as of July 1st of the Fellowship term.

2026 Entry Application

Opens on September 1st, 2025
Must be completed by October 10th, 2025

Interviews are conducted on a rolling basis

Application Requirements

Curriculum Vitae
Letter of Intent (Specific to Each Role)
Three Letters of Recommendation
Transcript of PharmD/PhD coursework

How to Apply

Interviews are conducted on a rolling basis, interested candidates may submit their letters of recommendation no later than 11/1/2025. Interested candidates may submit their application and supporting materials by scanning the QR code or visiting our application form and portal.

Program Email:

pharmacy.fellowship@howard.edu

Website:

<https://pharmacy.howard.edu/fellowship-program/about-fellowship-program>

